Document -

Athera Receives FDA Orphan Drug Designation for PC-mAb in prevention of vascular access failure in kidney disease patients

Athera announced today that FDA have granted Orphan Drug Designation to the fully human antibody PC-mAb for the treatment of patients with end stage renal disease, who are preparing for or undergo hemodialysis, to prevent vascular access failure. PC-mAb is designed to mimic endogenous antibodies to PC and act to support the immune response to vascular inflammation and thereby reduce complications.
go to media item
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
File format:
.pdf
Download

Contacts

Enter your email address to follow Athera Biotechnologies AB

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Athera Biotechnologies AB.

Okay